210 related articles for article (PubMed ID: 22542812)
41. Organised screening for cervical cancer in France: a cost-effectiveness assessment.
Barré S; Massetti M; Leleu H; De Bels F
BMJ Open; 2017 Oct; 7(10):e014626. PubMed ID: 28988162
[TBL] [Abstract][Full Text] [Related]
42. New cervical cancer screening strategy: combined Pap and HPV testing.
Jin XW; Zanotti K; Yen-Lieberman B
Cleve Clin J Med; 2005 Feb; 72(2):141-8. PubMed ID: 15757169
[TBL] [Abstract][Full Text] [Related]
43. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
[TBL] [Abstract][Full Text] [Related]
44. Knowledge of the HPV status biases cytotechnologists' interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy.
Doxtader EE; Brainard JA; Underwood D; Chute DJ
Cancer Cytopathol; 2017 Jan; 125(1):60-69. PubMed ID: 27731938
[TBL] [Abstract][Full Text] [Related]
45. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile.
Ferreccio C; Barriga MI; Lagos M; Ibáñez C; Poggi H; González F; Terrazas S; Katki HA; Núñez F; Cartagena J; Van De Wyngard V; Viñales D; Brañes J
Int J Cancer; 2013 Feb; 132(4):916-23. PubMed ID: 22684726
[TBL] [Abstract][Full Text] [Related]
46. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.
Cox JT
Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S15-25. PubMed ID: 16729900
[TBL] [Abstract][Full Text] [Related]
47. A mobile unit: an effective service for cervical cancer screening among rural Thai women.
Swaddiwudhipong W; Chaovakiratipong C; Nguntra P; Mahasakpan P; Tatip Y; Boonmak C
Int J Epidemiol; 1999 Feb; 28(1):35-9. PubMed ID: 10195661
[TBL] [Abstract][Full Text] [Related]
48. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
[TBL] [Abstract][Full Text] [Related]
49. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.
Wong AK; Chan RC; Nichols WS; Bose S
Cancer; 2009 Feb; 115(4):823-32. PubMed ID: 19127558
[TBL] [Abstract][Full Text] [Related]
50. Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort.
Mills JM; Morgan JR; Dhaliwal A; Perkins RB
Gynecol Oncol; 2021 Aug; 162(2):308-314. PubMed ID: 34090706
[TBL] [Abstract][Full Text] [Related]
51. Differences in cervical cancer screening and follow-up for black and white women in the United States.
Ford S; Tarraf W; Williams KP; Roman LA; Leach R
Gynecol Oncol; 2021 Feb; 160(2):369-374. PubMed ID: 33323276
[TBL] [Abstract][Full Text] [Related]
52. A decision support system based on an ensemble of random forests for improving the management of women with abnormal findings at cervical cancer screening.
Bountris P; Haritou M; Pouliakis A; Karakitsos P; Koutsouris D
Annu Int Conf IEEE Eng Med Biol Soc; 2015 Aug; 2015():8151-6. PubMed ID: 26738186
[TBL] [Abstract][Full Text] [Related]
53. Primary and Triage Cervical Screening Diagnostic Value of Methods for the Detection of Cervical Dysplasia.
Njue JK; Muturi M; Kamau L; Lwembe R
Biomed Res Int; 2022; 2022():1930102. PubMed ID: 36164451
[TBL] [Abstract][Full Text] [Related]
54. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
[TBL] [Abstract][Full Text] [Related]
55. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
[TBL] [Abstract][Full Text] [Related]
56. Persistent Disparities in Cervical Cancer Screening Uptake: Knowledge and Sociodemographic Determinants of Papanicolaou and Human Papillomavirus Testing Among Women in the United States.
Johnson NL; Head KJ; Scott SF; Zimet GD
Public Health Rep; 2020; 135(4):483-491. PubMed ID: 32516053
[TBL] [Abstract][Full Text] [Related]
57. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities.
Andersson S; Dillner L; Elfgren K; Mints M; Persson M; Rylander E
Acta Obstet Gynecol Scand; 2005 Oct; 84(10):996-1000. PubMed ID: 16167918
[TBL] [Abstract][Full Text] [Related]
58. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
59. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
60. Are Health Care Professionals Prepared to Implement Human Papillomavirus Testing? A Review of Psychosocial Determinants of Human Papillomavirus Test Acceptability in Primary Cervical Cancer Screening.
Tatar O; Wade K; McBride E; Thompson E; Head KJ; Perez S; Shapiro GK; Waller J; Zimet G; Rosberger Z
J Womens Health (Larchmt); 2020 Mar; 29(3):390-405. PubMed ID: 31479381
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
